№ lp_2_3_37191
File format: docx
Character count: 92388
File size: 556 KB
Version:
2.1
Executive Lead:
Executive Director of Quality and Medical Leadership
Lead Author:
Principal Clinical Pharmacist
Approved Date:
14/11/2022
Approved By:
Drugs and Therapeutics Committee (DTC)
Ratified Date:
14/11/2022
Ratified By:
Drugs and Therapeutics Committee (DTC)
Issue Date:
08/02/2023
Expiry Date:
14/11/2025
Target Audience:
Clinical staff
Document Type:
Guidelines
Ratifying Committee:
Drugs and Therapeutics Committee (DTC)
Review Date:
14/11/2025
Summary of significant changes from previous version:
Minor amendments: References to Xeplion® LAI in the document changed to Paliperidone monthly LAI as generic version available
Purpose:
Provide clinical staff with clear guidance on prescribing antipsychotics for the management of psychosis / schizophrenia in adults.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region:
Massachusetts, USA
Subject:
Healthcare billing, Antipsychotic medications
Document Type:
Policy / Instruction
Organization:
MassHealth
Audience:
In-state acute inpatient hospital providers
Effective Date:
5/15/2024
Reference:
Sections 5.B.4.g of the MassHealth Acute Hospital Request for Applications
Medication Covered:
Long-Acting Injectable (LAI) Antipsychotics
Billing Codes:
National Drug Code (NDC), HCPCS
Submission Requirements:
Professional claims (Claim Types M and B), Direct Data Entry for IC drugs, invoice attachment from distributor/manufacturer
Payment Methodology:
Fee schedule in 101 CMR 317.00 or Individual Consideration (IC)
Documentation:
Attachments via Provider Online Service Center (POSC)
Compliance Notes:
Failure to follow instructions may result in inaccurate payment
Instruction Updates:
May be updated from time to time
Year:
2023
Region / city:
UK, France, Italy
Topic:
Antipsychotics, Autism Spectrum Disorder, Clinical Trials
Document type:
Systematic review, Meta-analysis
Author(s):
Professor Shoumitro (Shoumi) Deb, Dr Meera Roy, Miss Bharati Limbu, Dr Basma Akrout Brizard, Dr Meena Murugan, Professor Ashok Roy, Dr Jacopo Santambrogio
Target audience:
Researchers, clinicians, healthcare professionals
Period of validity:
Not specified
Approval date:
4th July 2022
Date of changes:
Not specified
Language:
English
Keywords:
Antipsychotics, Autism, Meta-analysis, Randomised Controlled Trials, Clinical Outcomes
Prospero registration number:
CRD42022343669
Abstract:
Despite unclear evidence to support the long-term use of antipsychotics for treating challenging behaviours in people with autism without psychiatric disorders, this practice remains common.
Document Type:
Application form
Programme Name:
Living Well with Psychosis community funding call
Submission Method:
Online grants management system SmartSimple
Subject Area:
Severe enduring mental illness
Relevant Conditions:
Schizophrenia, bipolar disorder, post-traumatic stress disorder
Maximum Funding Duration:
18 months
Target Applicants:
Organisations working with people affected by severe enduring mental illness
Required Information:
Applicant details, project summary, funding request, organisational experience, governance involvement
Financial Information Requested:
Total funding requested and intended use of funds
Geographical Scope:
Boroughs specified by applicant
Decision-Making Criteria Reference:
Eligibility and scoring criteria
Year:
2016
Region / city:
United Kingdom
Topic:
Safety seeking behaviours, psychosis, anxiety
Document type:
Research article
Institution:
The University of Manchester, The Psychosis Research Unit, Greater Manchester West Mental Health NHS Foundation Trust
Author:
Sarah Tully, Adrian Wells, Anthony P. Morrison
Target audience:
Researchers, mental health professionals
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Year:
Not specified
Region / city:
Not specified
Topic:
Mental health, psychosis
Document type:
Research article
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers, mental health professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
Not specified
Contextual description:
Research article analyzing demographic characteristics and interview features used to identify individuals at clinical high risk for psychosis and community controls.
Year:
Not specified
Region / City:
Not specified
Topic:
Neurological Disorders, Psychiatry, Neuroimaging
Document Type:
Scientific Supplementary Figure
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Clinicians
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Contextual Description:
A scientific supplement detailing post-hoc comparisons of FAT and FW between healthy controls, adolescent-onset schizophrenia, and adolescent-onset bipolar disorder with psychosis, using neuroimaging data.
Year:
2023
Region / City:
Global
Topic:
Mental Health, Psychosis, Schizophrenia
Document Type:
Research Protocol / Search Strategy
Organization:
N/A
Author:
N/A
Target Audience:
Researchers, Mental Health Professionals
Effective Period:
N/A
Approval Date:
N/A
Revision Date:
N/A
Keywords:
psychosis, schizophrenia, risk, treatment, early intervention, qualitative research, search strategy
Study title:
Prevalence of Pathogenic Antibodies in Psychosis 2 (PPiP2)
Principal Investigator:
Local PPiP2 researcher
Participant study ID:
[ID]
Date:
[Date]
Version:
[Version]
Year:
[Year]
Region / City:
[Region or city if mentioned]
Topic:
Medical Research, Psychiatric Studies
Document Type:
Consent Form
Institution:
University of Oxford
Author:
[Author(s) if available]
Target Audience:
Research Participants, Medical Professionals
Study Period:
[Study Period if mentioned]
Approval Date:
[Date of approval if mentioned]
Amendment Date:
[Date of amendments if mentioned]
Year:
2026
Organization:
The Royal College of Psychiatrists
Position:
Patient Representative or Carer Representative
Salary:
£140 per day
Contract Type:
3-Year Fixed Term
Location:
United Kingdom
Application Submission:
Email to [email protected]
Target Audience:
Applicants with relevant experience in patient or carer advocacy
Relevant Legislation:
Equality Act 2010
Member Programs:
Disability Confident employer scheme
Required Documents:
CV, Cover Letter, Diversity Monitoring Form
Year:
2025
Region / City:
United Kingdom
Topic:
Mental health, risk assessment
Document type:
Research study with supplementary materials
Institution:
Early Intervention in Psychosis Services
Authors:
Multiple clinicians and researchers
Target audience:
Mental health professionals
Study period:
12 months
Assessment tool:
Oxford Mental Illness and Violence (OxMIV)
Methodology:
Mixed methods (quantitative assessments and qualitative interviews)
Participants:
Clinicians and patients with carers
Supplementary materials:
OxMIV assessment data, clinician and patient characteristics, thematic analysis of interviews
Type of document:
Pharmaceutical Benefits Advisory Committee (PBAC) submission and assessment report
Medicine:
Aripiprazole long-acting injectable (AOM)
Dosage forms/strengths:
Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe; Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe
Brand:
Abilify Maintena
Sponsor:
Lundbeck Australia Pty Ltd
Purpose of submission:
Request for General Schedule Authority Required (STREAMLINED) PBS listing of AOM pre-filled syringe dose form
Indication:
Treatment of schizophrenia
Comparator:
AOM modified release injection vial kit (therapeutic vial kits)
Regulatory status:
TGA registered 7 May 2018 for acute and maintenance treatment of schizophrenia in adults and maintenance treatment of bipolar I disorder (monotherapy)
Previous PBAC consideration:
400 mg AOM PFS recommended July 2018; recommendation rescinded March 2023
Pricing basis:
Cost-minimisation versus AOM vial kit with equivalent pricing (no price premium)
Price levels referenced:
DPMQ, PTP, AEMP (current as of 1 June 2025)
Estimated PBS usage:
400,000 to <500,000 scripts over first six years (Year 1 10,000–<20,000; Year 6 100,457)
Indication listing conditions:
Authority Required (Streamlined); prescriber types include medical practitioners and nurse practitioners; general schedule (Code GE)
Year:
2023
Region / city:
Rohtak, Haryana
Topic:
Schizophrenia, Psychiatric Rehabilitation
Document Type:
Research Article
Organization / Institution:
Institute of Mental Health, Pt. B.D. Sharma University of Health Sciences, PGIMS
Author:
Dr. Aakanksha Kharb, Dr. Nandini Lamba, Dr. Pradeep Kumar
Target Audience:
Mental Health Professionals, Researchers, Medical Students
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Date:
10 October 2014
Event:
World Mental Health Day
Theme:
Living with schizophrenia
Institution:
University of Cape Town
Department:
Department of Psychiatry and Mental Health, University of Cape Town
Issued by:
UCT Communication and Marketing Department
Media Liaison Officer:
Kemantha Govender
Location:
Rosebank, South Africa
Research Focus:
Genetic and neuroscientific studies on schizophrenia
Population Studied:
Xhosa population of South Africa
Type of Document:
Press release
Contact Information:
Tel (021) 650 5672; Cell (084) 737 6522; [email protected]
Note:
Year
Theme:
Mental Health / Schizophrenia / Text Messaging
Document Type:
Moderator’s Guide
Author:
Michele
Target Audience:
People with Schizophrenia, Mental Health Professionals
Context:
A moderator’s guide for gathering feedback from individuals with schizophrenia on the effectiveness of text messaging for relapse prevention and symptom monitoring.
Year:
2023
Region / City:
Nanjing, Jiangsu Province, China
Topic:
Neuroscience, Psychiatry, Schizophrenia, Bipolar Disorder
Document Type:
Research Article
Organization / Institution:
Affiliated Brain Hospital of Nanjing Medical University
Author:
Yilin Tang, Ruiqiu Zhu, Yucheng Ling, Yifan Wang, Yingbo Dong, Peiyu Cao, Yuting Li, Qi Si, Guoxin Xu, Zhuma Jin, Yuxiu Sui
Target Audience:
Psychiatry researchers, neuroscientists, medical professionals
Period of Activity:
2023
Date of Approval:
2023
Date of Changes:
Not specified
Keywords:
Schizophrenia, Bipolar disorder, Psychosis symptoms, MRI, Basal ganglia
Abstract:
This study investigates the volume changes of basal ganglia subregions in patients with schizophrenia (SCZ), bipolar disorder (BD), and healthy controls (HC), with a focus on the relationship between these changes and psychotic symptoms.
Species accumulation curve and diversity indices comparison between schizophrenia and control groups
Year:
2026
Region / city:
Not specified
Subject:
Schizophrenia, Metabolomics
Document type:
Research figure and table
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Researchers in schizophrenia and metabolomics
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
Not specified
Region / City:
Not specified
Topic:
Neurological Disorders, Psychiatry, Neuroimaging
Document Type:
Scientific Supplementary Figure
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, Clinicians
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Contextual Description:
A scientific supplement detailing post-hoc comparisons of FAT and FW between healthy controls, adolescent-onset schizophrenia, and adolescent-onset bipolar disorder with psychosis, using neuroimaging data.
Year:
2023
Region / City:
Global
Topic:
Mental Health, Psychosis, Schizophrenia
Document Type:
Research Protocol / Search Strategy
Organization:
N/A
Author:
N/A
Target Audience:
Researchers, Mental Health Professionals
Effective Period:
N/A
Approval Date:
N/A
Revision Date:
N/A
Keywords:
psychosis, schizophrenia, risk, treatment, early intervention, qualitative research, search strategy
Year:
2001
Region / City:
United States
Theme:
Mental health, biography, film study
Document Type:
Educational assignment / discussion guide
Institution:
High school / college classroom
Author:
Not specified
Target Audience:
Students studying psychology or film
Related Work:
Film "A Beautiful Mind" directed by Ron Howard
Topics Covered:
Schizophrenia, biography, character analysis, treatment methods, critical thinking
Date Assigned:
Not specified
Due Date:
Friday (as mentioned in text)
Year:
2026
Region / City:
Not specified
Subject:
Mental Health / Psychiatry
Document Type:
Clinical Treatment Outline
Institution / Organization:
Not specified
Author:
Not specified
Target Audience:
Mental health professionals
Period of Application:
Initial and ongoing treatment phase
Diagnosis:
F20.9 Schizophrenia
Treatment Goals:
Social, relational, occupational improvement
Assessment Requirements:
Initial clinical assessments as needed
Therapist Characteristics:
Empathy, consistency, reliability
Treatment Location:
Facility-based or therapist’s office depending on patient needs
Interventions:
Role-playing, exposure exercises, individual therapy sessions
Treatment Emphasis:
Interpersonal and occupational skills
Treatment Nature:
Individual therapy, possible family involvement
Frequency and Duration:
Weekly sessions for 6–12 months
Medications:
Antipsychotics as prescribed
Adjunct Services:
Occupational therapy, medical monitoring
Prognosis:
Recovery defined by functional and social improvements; outcome depends on therapeutic relationship and adherence